

DERMATOLOGY (A-L)

PATIENT INFORMATION

| | | | | | | |
|-------------|-------|--------|---------|---------|---------------------|--|
| Name: | | | SSN: | DOB: | | |
| Address: | | | City: | State: | ZIP: | |
| Home Phone: | Cell: | Email: | Height: | Weight: | Gender: Female Male | |

INSURANCE INFORMATION (or attach copy of the cards)

| | | | | |
|----------------------|----------------|---------------|-----------|----------|
| Primary Insurance: | Policy Holder: | Relationship: | Policy #: | Group #: |
| Secondary Insurance: | Policy Holder: | Relationship: | Policy #: | Group #: |

CLINICAL INFORMATION

Primary Diagnosis: Moderate to Severe Plaque Psoriasis Psoriatic Arthritis Hidradenitis Suppurativa Atopic Dermatitis
 Alopecia Areata Pruiigo Nodularis Other: _____

| | | | | |
|--------------------------|--------------------|-----------------------|------|--------------------|
| Diagnosis Code (ICD-10): | Date of Diagnosis: | TB Test Completed On: | BSA: | Latex Allergy: Y N |
|--------------------------|--------------------|-----------------------|------|--------------------|

PRESCRIPTION INFORMATION (for IV medication attach a copy of the prescription)

ADBRY™ (tralokinumab-ldm) 150 mg PFS
 Induction: Inject 600 mg (4 x 150 mg) SUBQ
 Qty: 4 Refills: None
Maintenance:
 Inject 300 mg (2 x 150 mg) SUBQ every other week
 Inject 300 mg (2 x 150 mg) SUBQ every 4 weeks
 ADBRY™ Bridge Care™ Program:
 Inject 300 mg (2 x 150 mg) SUBQ every other week, starting on Day 15
 Qty: _____ Refills: _____

AMJEVITA™ (adalimumab-atto) PFS
 SureClick 40 mg/0.8 mL PFS 20 mg/0.4 mL PFS 40 mg/0.8 mL
 Induction: Inject 2 x 40 mg SUBQ
 Maintenance: 40 mg every other week starting 1 week after initial dose
 Qty: _____ Refills: _____

BIMZELX® (bimekizumab-bkzx) 160 mg PFS Bridge
 Induction: Inject 320 mg (2 x 160 mg) SUBQ at week 0, 4, 8, 12, and 16
 Qty: 10 syringes Refills: _____
 Maintenance: Inject 320 mg (2 x 160 mg) SUBQ every 8 weeks
 Qty: 2 syringes Refills: _____
 Hidradenitis Suppurativa: Inject 320 mg (2 x 160 mg) SUBQ at weeks 0, 2, 4, 6, 8, 10, 12, 14, and 16 then every 4 weeks thereafter
 Qty: 10 syringes Refills: _____

CIBINQO™ (abrocitinib) tablet 50 mg 100 mg 200 mg
 _____ mg PO once daily
 Qty: _____ Refills: _____

Cimzia® (certalizumab pegol) PFS
 Induction: Inject 2 x 200 mg/mL SUBQ at week 0, 2, and 4
 Qty: 6 syringes Refills: 0
Maintenance: 2 x 200 mg SUBQ every 4 weeks
 2 x 200 mg SUBQ every 2 weeks 200 mg SUBQ every 2 weeks
 Qty: 28 days Refills: _____

COSENTYX® (secukinumab)
 75 mg PFS
 Induction: Inject 300 mg (2 x 150 mg/mL) SUBQ week 0, 1, 2, 3, 4
 Qty: 10 Refills: 0
 Maintenance: Inject 300 mg SUBQ every 4 weeks
 Qty: 28 days Refills: _____
 150 mg 150 mg Sensoready® Pen Kit 150 mg PFS
 Induction: Inject 150 mg SUBQ week 0, 1, 2, 3, 4
 Qty: 5 Refills: _____
 Maintenance: Inject 150 mg SUBQ every 4 weeks
 Qty: 28 days Refills: _____
 300 mg UnoReady Pen (1 x 300 mg/2 mL)
 Sensoready® Pen Kit (2 x 150 mL) PFS (2 x 150 mL)
 Induction: Inject 300 mg SUBQ week 0, 1, 2, 3, 4
 Qty: 10 Refills: 0
 Maintenance: Inject 300 mg SUBQ every 4 weeks
 Qty: 28 days Refills: _____

DUPIXENT® (dupilumab) PFS pen
 Induction: Inject 2 x 300 mg (600 mg) SUBQ Day 1
 Qty: 2 for 14 days Refills: None
 Maintenance: Inject 300 mg SUBQ every other week
 Qty: 2 for 28 days Refills: _____

EBGLYSS™ (lebrikizumab-ibkz) pen
 Initial: Inject 500 mg (2 x 250 mg) SUBQ at week 0 and 2
 Qty: 4 pens Refills: None
 Induction: Inject 250 mg SUBQ every 2 weeks (weeks 4-14)
 Qty: 2 pens Refills: 2
 Maintenance: Inject 250 mg SUBQ every 4 weeks starting week 16
 Qty: 1 pen Refills: _____

ENBREL® (etanercept)
 Mini Cartridge PFS Autoinjector Vial
 Induction: Inject (50 mg) SUBQ twice weekly for three months
 Qty: 8 Refills: 2
Maintenance: 50 mg 25 mg
 Once weekly SUBQ Twice weekly SUBQ
 Qty: 8 4 Refills: _____

ERIVEDGE™ (vismodegib)
 150 mg capsule once daily PO, with or without food
 Qty: 28 days Refills: _____

HUMIRA® (adalimumab)
 pen PFS citrate free (CF) original formula
Hidradenitis Suppurativa Loading:
 160 mg SUBQ Day 1, 80 mg SUBQ Day 15
 80 mg SUBQ Day 1, 80 mg SUBQ Day 2, 80 mg SUBQ Day 15
 Psoriasis Loading: 80 mg SUBQ Day 1, 40 mg SUBQ Day 8, 40 mg SUBQ Day 22
 Qty: QS Other: _____ Refills: 0
 Hidradenitis Suppurativa Maintenance:
 40 mg SUBQ once weekly, beginning Day 29
 80 mg SUBQ every other week, beginning Day 29
 Psoriasis Maintenance: 40 mg SUBQ every other week
 Qty: QS for 1 month Other: _____ Refills: _____
 *Use 40 mg and/or 80 mg devices as needed to meet insurance and dispensing requirements.

ICOTYDE™ (icotrokinra) tablets
 200 mg tablets once daily PO, with or without food
 Qty: 30 Refills: _____

ILUMYA™ (tildrakizumab-asmn) PFS
 Induction: Inject 100 mg/mL SUBQ at weeks 0 and 4
 Qty: 2 Refills: None
 Maintenance: Inject 100 mg/mL SUBQ every 12 weeks
 Qty: _____ Refills: _____

INFLECTRA® (infliximab-dyyb) 100 mg vials
 3 mg/kg 5 mg/kg 10 mg/kg
 Induction: Give dose as an IV infusion at 0, 2, and 6 weeks
 Qty: _____ Refills: 2
 Maintenance: Give dose as an IV infusion every _____ weeks
 Qty: _____ Refills: 2

LEQSELVI™ (deuruxolitinib) tablets 8 mg PO twice daily
 Qty: _____ Refills: _____

LITFULO™ (ritlecitinib) capsule 50 mg PO once daily
 Qty: 28 Refills: _____

As required by your state, Prescriber to check "Dispense as written" or handwritten "Brand Medically Necessary" and sign to prevent generic substitution. Dispense as written

PHYSICIAN INFORMATION Injection Training: Office to Instruct SP to Arrange

| | | |
|-----------------------|----------|--|
| Prescriber Name: | Phone: | Fax: |
| Office Contact: | Email: | |
| Address: | City: | State: ZIP: |
| NPI #: | Tax ID#: | Ship To: <input type="checkbox"/> Patient <input type="checkbox"/> MD Office |
| Prescriber Signature: | Date: | |

PATIENT INFORMATION

| | | | | |
|-------------|-------|---------------------|---------|---------|
| Name: | | SSN: | DOB: | |
| Address: | | City: | State: | ZIP: |
| Home Phone: | Cell: | Email: | Height: | Weight: |
| | | Gender: Female Male | | |

INSURANCE INFORMATION (or attach copy of the cards)

| | | | | |
|----------------------|----------------|---------------|-----------|----------|
| Primary Insurance: | Policy Holder: | Relationship: | Policy #: | Group #: |
| Secondary Insurance: | Policy Holder: | Relationship: | Policy #: | Group #: |

CLINICAL INFORMATION

Primary Diagnosis: Moderate to Severe Plaque Psoriasis Psoriatic Arthritis Hidradenitis Suppurativa Atopic Dermatitis
 Alopecia Areata Prurigo Nodularis Other: _____

| | | | | |
|--------------------------|--------------------|-----------------------|------|--------------------|
| Diagnosis Code (ICD-10): | Date of Diagnosis: | TB Test Completed On: | BSA: | Latex Allergy: Y N |
|--------------------------|--------------------|-----------------------|------|--------------------|

PRESCRIPTION INFORMATION (for IV medication attach a copy of the prescription)

NEMLUVIO® (nemolizumab-ito) Auto Injector 30 mg/mL
 Prurigo Nodularis Induction: Inject 60 mg/mL (2 x 30 mg/mL) SUBQ
Qty: 2 **Refills:** None
Maintenance: Patients weighing < 90kg Inject 30 mg/mL SUBQ every 4 weeks
 Patients weighing ≥ 90kg Inject 60 mg/mL (2 x 30 mg/mL) SUBQ every 4 weeks
Qty: _____ **Refills:** _____
 Atopic Dermatitis Induction: Inject 60 mg/mL (2 x 30 mg/mL) SUBQ
Qty: 2 **Refills:** None
Maintenance: Inject 30 mg/mL SUBQ every 4 weeks
 After week 16 Inject 30 mg/mL SUBQ every 8 weeks
Qty: _____ **Refills:** _____

ODOMZO® (sonidegib) capsule
 200 mg on an empty stomach, at least 1 hr before or 2 hrs after a meal
Qty: 30 **Refills:** _____

OLUMIANT® (baricitinib) tablet
 2 mg PO once daily 4 mg PO once daily
Qty: _____ **Refills:** _____

OTEZLA® (apremilast)
 Titration Pack: PO as directed per package instructions
Qty: 1 Pack **Refills:** 0
 Maintenance: (30 mg) PO twice daily
Qty: 30 days **Refills:** _____

OTEZLA XR™ (apremilast) 75 mg tablets
 Once daily PO with or without food
Qty: 30 days 90 days **Refills:** _____

REMICADE® (infliximab) 100 mg vial Biosimilar authorized
 Induction: 5 mg/kg as an IV infusion at 0, 2, and 6 weeks
Qty: 1 dose **Refills:** 2
 Maintenance: 5 mg/kg as an IV infusion every 8 weeks
Qty: _____ **Refills:** _____

RINVOQ® (upadacitinib) extended-release tablet
 15 mg 30 mg
Once daily PO with or without food
Qty: _____ **Refills:** _____

RHAPSIDO® (remibrutinib) tablets 25 mg
 Twice daily PO with or without food
Qty: 60 tablets 180 tablets **Refills:** _____

SILIQ® (brodalumab) PFS
 Induction: Inject 210 mg SUBQ weeks 0 and 1
Qty: 2 **Refills:** 0
 Maintenance: Starting at Week 2 of therapy, inject 210 mg SUBQ every 2 weeks
Qty: 2 **Refills:** _____

SIMLANDI® (adalimumab-ryvk) AutoInjector 40 mg/0.4 mL
 Induction: Inject 40 mg SUBQ every week.
 Inject 40 mg SUBQ every other week. Inject 80 mg SUBQ every other week.
Quantity: 28 days **Refills:** _____
 Maintenance: Inject 80 mg SUBQ Day 1, followed by 40 mg every other week starting one week after initial dose
 Inject 160 mg SUBQ on Day 1, (given in one day or split over two consecutive days), then 80 mg on Day 15
 Begin 40 mg weekly or 80 mg every other week dosing two weeks later starting Day 29
Quantity: 84 days **Refills:** _____

SIMPON® (golimumab) PFS Autoinjector
 Inject 50 mg SUBQ once a month
Qty: 1 **Refills:** _____

SKYRIZI™ (risankizumab-rzaa) PFS pen
 Inject 150 mg (1 injection) SUBQ at Week 0, Week 4
Qty: 2 syringes **Refills:** _____
 Maintenance: Inject 150 mg SUBQ every 12 weeks
Qty: _____ **Refills:** _____

STELARA® (ustekinumab) 45 mg PFS 90 mg PFS
 Induction: Inject contents of 1 syringe SUBQ on Day 0 and Day 28
Qty: 1 syringe **Refills:** 1
 Maintenance: Inject contents of 1 syringe SUBQ every 12 weeks
Qty: 1 syringe **Refills:** _____

SOTYKTU™ (deucravacitinib) 6 mg tablet
 Once daily PO with or without food
Qty: _____ **Refills:** _____

TALTZ® (ixekizumab) citrate free (CF) Autoinjector PFS
 Psoriasis Induction: Inject 160 mg (2 x 80 mg) SUBQ at week 0; Inject 80 mg at weeks 2, 4, 6, 8, 10, 12
Qty: 8 **Refills:** 0
 Psoriatic Arthritis Induction: Inject 160 mg (2 x 80 mg) SUBQ at week 0
Qty: 2 **Refills:** 0
 Maintenance: 80 mg SUBQ every 4 weeks
Qty: 1 **Refills:** _____

TREMFYA® (guselkumab) PFS Autoinjector
 Induction: Inject 100 mg SUBQ weeks 0 and 4
Qty: 1 **Refills:** 1
 Maintenance: Inject 100 mg SUBQ every 8 weeks
Qty: 1 **Refills:** _____

OTHER

STRENGTH: _____

SIG/DIRECTIONS: _____

QUANTITY: _____ **REFILLS:** _____

As required by your state, Prescriber to check "Dispense as written" or handwritten "Brand Medically Necessary" and sign to prevent generic substitution.

PHYSICIAN INFORMATION

Injection Training: Office to Instruct SP to Arrange Teaching

| | | | |
|-----------------------|----------|--|------|
| Prescriber Name: | Phone: | Fax: | |
| Office Contact: | Email: | | |
| Address: | City: | State: | ZIP: |
| NPI #: | Tax ID#: | Ship To: <input type="checkbox"/> Patient <input type="checkbox"/> MD Office | |
| Prescriber Signature: | Date: | | |